All patients
Age < 65y (younger) Age > 65y BRAF mutant BRAF wild type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN previous systemic treatment (%) previous systemic treatment NO (%) stage IIIa stage IIIb stage IIIc stage M0 stage M0/M1A/M1B stage M1A stage M1B stage M1C stage M1C (with brain metastasis)
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
melanoma (ML), anti-CTLA-4 vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results A3671009, 2013 0.88 [0.75; 1.04]
Ascierto (ipi 10 vs 3 mg/kg), 2017 0.84 [0.71; 1.00]
CA184-024, 2011 0.72 [0.59; 0.87]
CheckMate 067 (N vs I ; all population), 2015 0.63 [0.48; 0.82]
CheckMate 067 (NI vs I ; all population), 2015 0.55 [0.42; 0.72]
CheckMate 069 (all population), 2015 0.74 [0.43; 1.27]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 1.44 [0.46; 4.49]
CheckMate 238, 2017 0.87 [0.66; 1.14]
EORTC 18071, 2015 0.72 [0.58; 0.89]
KEYNOTE-006 (2 week), 2015 0.63 [0.47; 0.84]
KEYNOTE-006 (3 week), 2015 0.69 [0.52; 0.91]
MDX010 Ipi plus gp100 vs gp100, 2010 0.68 [0.55; 0.85]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.04 [0.83; 1.30]
MDX010 Ipi vs gp100, 2010 0.66 [0.51; 0.86]
0.75 [0.68 ; 0.82 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 14 51% 7,640 low low deaths (OS) (extension)detailed results CA184-024, 2011 0.69 [0.57; 0.84]
CheckMate 067 (N vs I ; all population), 2015 0.63 [0.52; 0.76]
CheckMate 067 (NI vs I ; all population), 2015 0.52 [0.42; 0.64]
EORTC 18071, 2015 0.73 [0.64; 0.83]
KEYNOTE-006 (2 week), 2015 0.68 [0.53; 0.87]
KEYNOTE-006 (3 week), 2015 0.68 [0.53; 0.87]
0.66 [0.60 ; 0.73 ] CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 36% 3,323 low not evaluable MFSdetailed results CheckMate 238, 2017 0.73 [0.56; 0.96]
EORTC 18071, 2015 0.76 [0.63; 0.91]
0.75 [0.65 ; 0.87 ] CheckMate 238, 2017, EORTC 18071, 2015 2 0% 1,686 low not evaluable MFS (extension)detailed results EORTC 18071, 2015 0.76 [0.64; 0.90]
0.76 [0.64 ; 0.90 ] EORTC 18071, 2015 1 0% 951 NA not evaluable PFS (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 0.53 [0.44; 0.64]
CheckMate 067 (NI vs I ; all population), 2015 0.42 [0.35; 0.51]
CheckMate 069 (all population), 2015 0.36 [0.23; 0.57]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.47 [0.10; 2.27]
KEYNOTE-006 (2 week), 2015 0.61 [0.50; 0.75]
KEYNOTE-006 (3 week), 2015 0.61 [0.50; 0.75]
0.52 [0.44 ; 0.61 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 59% 2,547 low not evaluable progression or deaths (PFS)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.89 [0.66; 1.21]
CA184-024, 2011 0.76 [0.63; 0.92]
CheckMate 067 (N vs I ; all population), 2015 0.57 [0.43; 0.76]
CheckMate 067 (NI vs I ; all population), 2015 0.42 [0.31; 0.57]
CheckMate 069 (all population), 2015 0.38 [0.23; 0.63]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 0.38 [0.15; 0.98]
CheckMate 069 (BRAF wild type), 2015 0.40 [0.23; 0.69]
KEYNOTE-006 (2 week), 2015 0.58 [0.46; 0.73]
KEYNOTE-006 (3 week), 2015 0.58 [0.47; 0.72]
0.57 [0.48 ; 0.68 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 9 66% 3,885 low not evaluable RFS (extension)detailed results CheckMate 238, 2017 0.71 [0.59; 0.85]
EORTC 18071, 2015 0.75 [0.63; 0.89]
0.73 [0.65 ; 0.83 ] CheckMate 238, 2017, EORTC 18071, 2015 2 0% 1,857 low not evaluable RFS/DFSdetailed results CheckMate 238, 2017 0.65 [0.51; 0.83]
EORTC 18071, 2015 0.75 [0.63; 0.89]
0.72 [0.62 ; 0.82 ] CheckMate 238, 2017, EORTC 18071, 2015 2 0% 1,857 low not evaluable DCRdetailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.19 [0.86; 1.63]
CA184-024, 2011 1.15 [0.79; 1.68]
1.17 [0.92 ; 1.50 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011 2 0% 1,229 low not evaluable DORdetailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.68 [0.55; 0.85]
0.68 [0.55 ; 0.85 ] MDX010 Ipi plus gp100 vs gp100, 2010 1 0% 25 NA not evaluable objective responses (ORR)detailed results A3671009, 2013 1.14 [0.69; 1.88]
Ascierto (ipi 10 vs 3 mg/kg), 2017 1.31 [0.86; 2.00]
CA184-024, 2011 1.56 [0.91; 2.65]
CheckMate 067 (N vs I ; all population), 2015 3.40 [2.02; 5.72]
CheckMate 067 (NI vs I ; all population), 2015 6.11 [3.59; 10.39]
CheckMate 069 (all population), 2015 15.08 [8.07; 28.17]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.82 [0.45; 212.91]
CheckMate 069 (BRAF wild type), 2015 12.96 [3.47; 48.38]
KEYNOTE-006 (2 week), 2015 3.77 [2.43; 5.86]
KEYNOTE-006 (3 week), 2015 3.63 [2.34; 5.65]
MDX010 Ipi plus gp100 vs gp100, 2010 4.06 [0.94; 17.43]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.49 [0.25; 0.97]
MDX010 Ipi vs gp100, 2010 8.24 [1.85; 36.76]
3.20 [1.90 ; 5.38 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 13 88% 5,892 low low objective responses (ORR) (extension)detailed results CheckMate 067 (N vs I ; all population), 2015 3.54 [2.46; 5.10]
CheckMate 067 (NI vs I ; all population), 2015 6.35 [4.38; 9.21]
CheckMate 069 (all population), 2015 12.20 [4.41; 33.76]
CheckMate 069 (BRAF mutant) EXPLORATORY, 2015 9.80 [0.45; 211.42]
CheckMate 069 (BRAF wild type), 2015 13.00 [3.48; 48.60]
6.30 [3.76 ; 10.57 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF mutant) EXPLORATORY, 2015, CheckMate 069 (BRAF wild type), 2015 5 60% 1,544 low not evaluable AE (any grade)detailed results A3671009, 2013 2.22 [1.12; 4.38]
CA184-024, 2011 5.17 [1.48; 18.09]
CheckMate 238, 2017 0.49 [0.20; 1.23]
EORTC 18071, 2015 7.53 [3.17; 17.90]
MDX010 Ipi plus gp100 vs gp100, 2010 1.95 [0.54; 7.01]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.96 [0.55; 7.07]
MDX010 Ipi vs gp100, 2010 0.99 [0.24; 4.05]
2.10 [1.00 ; 4.39 ] A3671009, 2013, CA184-024, 2011, CheckMate 238, 2017, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 72% 4,278 low not evaluable AE (grade 3-4)detailed results A3671009, 2013 1.84 [1.35; 2.52]
CA184-024, 2011 3.39 [2.34; 4.94]
CheckMate 238, 2017 0.28 [0.21; 0.37]
EORTC 18071, 2015 0.11 [0.08; 0.17]
MDX010 Ipi plus gp100 vs gp100, 2010 0.94 [0.63; 1.40]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.99 [0.66; 1.47]
MDX010 Ipi vs gp100, 2010 0.95 [0.59; 1.55]
0.78 [0.32 ; 1.88 ] A3671009, 2013, CA184-024, 2011, CheckMate 238, 2017, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 98% 4,278 low not evaluable AE leading to death (grade 5)detailed results A3671009, 2013 1.71 [0.85; 3.45]
CA184-024, 2011 1.02 [0.02; 51.42]
1.68 [0.84 ; 3.36 ] A3671009, 2013, CA184-024, 2011 2 0% 1,142 moderate not evaluable AE leading to treatment discontinuation (any grade)detailed results A3671009, 2013 97.13 [5.95; 1585.40]
CheckMate 238, 2017 0.15 [0.10; 0.21]
3.22 [0.01 ; 1878.15 ] A3671009, 2013, CheckMate 238, 2017 2 95% 1,549 low not evaluable AE leading to treatment discontinuation (grade 3-4)detailed results CheckMate 238, 2017 0.11 [0.07; 0.18]
0.11 [0.07 ; 0.18 ] CheckMate 238, 2017 1 0% 905 NA not evaluable SAE (any grade)detailed results A3671009, 2013 3.19 [2.19; 4.65]
3.19 [2.19 ; 4.65 ] A3671009, 2013 1 0% 644 NA not evaluable STRAE (any grade)detailed results KEYNOTE-006 (2 week), 2015 0.67 [0.41; 1.09]
KEYNOTE-006 (3 week), 2015 0.63 [0.39; 1.03]
0.65 [0.46 ; 0.92 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable STRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable TRAE (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.40 [1.76; 3.28]
CA184-024, 2011 5.64 [3.80; 8.35]
CheckMate 067 (N vs I ; all population), 2015 1.01 [0.64; 1.59]
CheckMate 067 (NI vs I ; all population), 2015 3.70 [1.95; 7.04]
CheckMate 069 (all population), 2015 0.75 [0.19; 2.97]
CheckMate 238, 2017 0.25 [0.15; 0.43]
EORTC 18071, 2015 14.40 [10.07; 20.60]
KEYNOTE-006 (2 week), 2015 1.62 [1.07; 2.46]
KEYNOTE-006 (3 week), 2015 1.16 [0.78; 1.72]
MDX010 Ipi plus gp100 vs gp100, 2010 2.17 [1.28; 3.67]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.99 [1.17; 3.41]
MDX010 Ipi vs gp100, 2010 1.09 [0.60; 1.98]
1.86 [1.01 ; 3.42 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 12 95% 6,815 low low TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.70 [1.86; 3.92]
CA184-024, 2011 11.25 [6.30; 20.10]
CheckMate 067 (N vs I ; all population), 2015 0.71 [0.49; 1.03]
CheckMate 067 (NI vs I ; all population), 2015 3.83 [2.74; 5.36]
CheckMate 069 (all population), 2015 3.77 [1.71; 8.31]
CheckMate 238, 2017 0.20 [0.14; 0.27]
EORTC 18071, 2015 25.27 [14.14; 45.18]
KEYNOTE-006 (2 week), 2015 0.84 [0.54; 1.30]
KEYNOTE-006 (3 week), 2015 0.82 [0.53; 1.28]
MDX010 Ipi plus gp100 vs gp100, 2010 1.64 [0.90; 2.99]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.17 [0.68; 2.01]
MDX010 Ipi vs gp100, 2010 1.41 [0.69; 2.88]
1.92 [0.90 ; 4.12 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 12 97% 6,815 low low TRAE leading to death (grade 5)detailed results A3671009, 2013 7.00 [0.86; 57.23]
Ascierto (ipi 10 vs 3 mg/kg), 2017 2.00 [0.36; 10.99]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 238, 2017 0.25 [0.01; 5.55]
EORTC 18071, 2015 10.16 [0.55; 186.52]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 1.36 [0.28; 6.47]
1.94 [0.85 ; 4.40 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010 9 0% 6,074 low not evaluable TRAE leading to discontinuation (any grade)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.97 [1.40; 2.78]
CheckMate 067 (N vs I ; all population), 2015 0.72 [0.45; 1.13]
CheckMate 067 (NI vs I ; all population), 2015 3.99 [2.72; 5.85]
CheckMate 069 (all population), 2015 4.18 [1.76; 9.91]
CheckMate 069 (BRAF wild type), 2015 3.39 [1.40; 8.19]
CheckMate 238, 2017 0.12 [0.08; 0.17]
EORTC 18071, 2015 21.35 [13.41; 33.97]
KEYNOTE-006 (2 week), 2015 0.74 [0.39; 1.40]
KEYNOTE-006 (3 week), 2015 1.23 [0.69; 2.18]
1.77 [0.61 ; 5.13 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 069 (BRAF wild type), 2015, CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 9 98% 5,139 low not evaluable TRAE leading to discontinuation (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.27 [1.53; 3.38]
CheckMate 067 (N vs I ; all population), 2015 0.52 [0.31; 0.88]
CheckMate 067 (NI vs I ; all population), 2015 2.72 [1.82; 4.06]
CheckMate 069 (all population), 2015 4.14 [1.59; 10.74]
CheckMate 238, 2017 0.09 [0.05; 0.15]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.00 [0.30 ; 3.37 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 96% 4,086 low not evaluable Abdominal pain TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 069 (all population), 2015 0.24 [0.01; 7.31]
CheckMate 238, 2017 0.50 [0.02; 14.96]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.45 [0.12 ; 1.68 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 3,360 low not evaluable Adrenal insufficiency TRAE (grade 3-4)detailed results A3671009, 2013 5.93 [0.30; 118.96]
Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 069 (all population), 2015 0.24 [0.02; 2.68]
CheckMate 238, 2017 0.50 [0.09; 2.74]
MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.30 [0.55 ; 3.04 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 9 0% 4,949 low not evaluable Alopecia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Anaemia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 1.85 [0.17; 20.50]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.16 [0.16 ; 8.29 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Arthralgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 0.50 [0.05; 5.53]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.05 [0.27 ; 4.00 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 3,360 low not evaluable Asthenia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.04; 5.49]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 0.25 [0.03; 2.24]
KEYNOTE-006 (2 week), 2015 0.46 [0.04; 5.09]
KEYNOTE-006 (3 week), 2015 0.23 [0.01; 5.12]
0.38 [0.13 ; 1.09 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 3,360 low not evaluable Chills TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.75 [0.08 ; 7.20 ] CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,207 moderate not evaluable Colitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.16 [0.96; 4.84]
CA184-024, 2011 10.35 [0.56; 190.49]
CheckMate 067 (N vs I ; all population), 2015 0.12 [0.03; 0.39]
CheckMate 067 (NI vs I ; all population), 2015 1.08 [0.61; 1.93]
CheckMate 069 (all population), 2015 2.94 [0.81; 10.66]
EORTC 18071, 2015 39.14 [5.34; 286.74]
KEYNOTE-006 (2 week), 2015 0.19 [0.06; 0.58]
KEYNOTE-006 (3 week), 2015 0.34 [0.14; 0.83]
MDX010 Ipi plus gp100 vs gp100, 2010 8.58 [0.50; 146.20]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.58 [0.22; 1.50]
MDX010 Ipi vs gp100, 2010 14.85 [0.83; 264.38]
1.32 [0.57 ; 3.09 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 11 82% 5,910 low low Constipation TRAE (grade 3-4)detailed results CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.94 [0.11 ; 8.13 ] CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,207 moderate not evaluable Cough TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 3.99 [0.18; 88.92]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.56 [0.25 ; 9.72 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 2,315 low not evaluable Decreased appetite TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 4.01 [0.45; 36.11]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.42 [0.34 ; 5.93 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 5 0% 2,455 low serious Diabetes TRAE (grade 3-4)detailed results CheckMate 238, 2017 2.01 [0.07; 59.97]
KEYNOTE-006 (3 week), 2015 1.85 [0.06; 55.43]
1.93 [0.17 ; 21.31 ] CheckMate 238, 2017, KEYNOTE-006 (3 week), 2015 2 0% 1,438 low not evaluable Diarrhoea TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.84 [1.05; 3.21]
CA184-024, 2011 21.14 [1.23; 363.94]
CheckMate 067 (N vs I ; all population), 2015 0.48 [0.21; 1.09]
CheckMate 067 (NI vs I ; all population), 2015 1.66 [0.90; 3.06]
CheckMate 069 (all population), 2015 0.98 [0.31; 3.04]
CheckMate 238, 2017 0.15 [0.07; 0.34]
EORTC 18071, 2015 25.54 [6.16; 105.87]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.39 [0.10; 1.52]
MDX010 Ipi plus gp100 vs gp100, 2010 5.01 [0.65; 38.48]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.80 [0.30; 2.12]
MDX010 Ipi vs gp100, 2010 6.29 [0.75; 52.98]
1.48 [0.69 ; 3.17 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 12 82% 6,815 low low Dry skin TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.37 [0.62; 3.04]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.32 [0.62 ; 2.79 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 2,315 low not evaluable Dyspnoea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 6.01 [0.30; 120.48]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.78 [0.45 ; 7.09 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 5 0% 2,455 low not evaluable Endocrine disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.30 [0.99; 5.36]
CheckMate 069 (all population), 2015 1.24 [0.23; 6.63]
EORTC 18071, 2015 42.70 [5.84; 312.15]
MDX010 Ipi plus gp100 vs gp100, 2010 2.80 [0.15; 53.28]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.27 [0.07; 1.01]
MDX010 Ipi vs gp100, 2010 10.44 [0.56; 193.00]
2.62 [0.67 ; 10.32 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 069 (all population), 2015, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 6 74% 3,097 low not evaluable Eye disorders TRAE (grade 3-4)detailed results A3671009, 2013 0.98 [0.02; 49.62]
Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.66 [0.05 ; 8.68 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017 2 0% 1,370 low not evaluable Fatigue TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.20; 4.96]
CheckMate 067 (NI vs I ; all population), 2015 4.45 [1.26; 15.77]
CheckMate 069 (all population), 2015 5.11 [0.27; 95.65]
CheckMate 238, 2017 0.50 [0.09; 2.74]
KEYNOTE-006 (2 week), 2015 0.30 [0.03; 2.95]
KEYNOTE-006 (3 week), 2015 0.92 [0.18; 4.62]
1.25 [0.51 ; 3.02 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 34% 3,360 low not evaluable Febrile neutropenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Gastrointestinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.82 [1.14; 2.91]
CheckMate 069 (all population), 2015 2.22 [0.77; 6.34]
CheckMate 238, 2017 0.10 [0.05; 0.20]
EORTC 18071, 2015 22.61 [8.20; 62.34]
MDX010 Ipi plus gp100 vs gp100, 2010 8.05 [1.07; 60.32]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.74 [0.34; 1.61]
MDX010 Ipi vs gp100, 2010 10.83 [1.37; 85.84]
2.23 [0.58 ; 8.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 94% 4,002 low not evaluable Guillain-Barré syndrome TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Headache TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 069 (all population), 2015 1.98 [0.09; 44.77]
CheckMate 238, 2017 0.14 [0.02; 1.15]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.64 [0.20 ; 2.07 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 3,360 low not evaluable Hepatitis TRAE (grade 3-4)detailed results A3671009, 2013 3.94 [0.18; 87.81]
Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
CA184-024, 2011 6.16 [0.31; 123.62]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 10.08 [0.55; 185.32]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
KEYNOTE-006 (2 week), 2015 2.78 [0.29; 26.92]
KEYNOTE-006 (3 week), 2015 4.69 [0.54; 40.40]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
2.76 [1.23 ; 6.19 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 11 0% 5,609 low low Hepatobiliary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 15.93 [0.93; 273.74]
CheckMate 238, 2017 0.15 [0.07; 0.32]
EORTC 18071, 2015 57.44 [7.90; 417.44]
MDX010 Ipi plus gp100 vs gp100, 2010 0.46 [0.10; 2.07]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 2.78 [0.15; 52.88]
MDX010 Ipi vs gp100, 2010 0.16 [0.01; 3.32]
1.61 [0.20 ; 13.18 ] CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 6 87% 3,276 low not evaluable Hypersensitivity TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.01 [0.30; 120.38]
CheckMate 238, 2017 2.01 [0.07; 59.97]
3.72 [0.39 ; 35.19 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 238, 2017 2 0% 1,631 low not evaluable Hyperthyroidism TRAE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 6.01 [0.30; 120.48]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 1.00 [0.06; 16.07]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
1.03 [0.29 ; 3.72 ] CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 0% 3,858 low not evaluable Hypophysitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.43 [0.54; 3.81]
CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.28; 3.47]
CheckMate 069 (all population), 2015 0.48 [0.07; 3.51]
CheckMate 238, 2017 0.18 [0.04; 0.81]
EORTC 18071, 2015 44.19 [2.67; 732.31]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.05; 2.45]
MDX010 Ipi vs gp100, 2010 4.08 [0.18; 91.29]
0.75 [0.34 ; 1.65 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 11 44% 6,317 low low Hypothyroidism TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CA184-024, 2011 1.02 [0.02; 51.42]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
CheckMate 238, 2017 0.50 [0.05; 5.53]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.94 [0.33 ; 2.64 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 11 0% 5,870 low low Increase AST TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.11 [1.01; 65.20]
CA184-024, 2011 52.70 [7.19; 385.99]
CheckMate 067 (N vs I ; all population), 2015 1.50 [0.25; 9.01]
CheckMate 067 (NI vs I ; all population), 2015 9.98 [2.31; 43.24]
CheckMate 069 (all population), 2015 7.32 [0.41; 131.94]
CheckMate 238, 2017 0.10 [0.02; 0.44]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs gp100, 2010 0.17 [0.02; 1.91]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.55 [0.40 ; 6.04 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 11 76% 5,870 low low Increased ALT TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 6.14 [1.36; 27.62]
CA184-024, 2011 32.40 [7.79; 134.72]
CheckMate 067 (N vs I ; all population), 2015 0.79 [0.21; 2.98]
CheckMate 067 (NI vs I ; all population), 2015 5.78 [2.20; 15.21]
CheckMate 069 (all population), 2015 10.83 [0.62; 189.76]
CheckMate 238, 2017 0.18 [0.07; 0.48]
KEYNOTE-006 (2 week), 2015 0.23 [0.01; 5.10]
KEYNOTE-006 (3 week), 2015 0.46 [0.04; 5.11]
MDX010 Ipi plus gp100 vs gp100, 2010 1.39 [0.06; 31.06]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.38 [0.06; 30.82]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.85 [0.55 ; 6.29 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 11 81% 5,870 low low Increased lipase level TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 067 (N vs I ; all population), 2015 1.17 [0.53; 2.56]
CheckMate 067 (NI vs I ; all population), 2015 3.04 [1.54; 5.98]
CheckMate 069 (all population), 2015 4.19 [0.51; 34.53]
2.09 [1.14 ; 3.84 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015 4 19% 2,114 low not evaluable Infusion-related reactions TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Maculopapular rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CheckMate 067 (N vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
CheckMate 238, 2017 0.05 [0.00; 0.95]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.25 [0.38 ; 4.09 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 7 22% 4,086 low not evaluable Myalgia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
KEYNOTE-006 (2 week), 2015 0.92 [0.06; 14.80]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.99 [0.22 ; 4.36 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 5 0% 2,455 low not evaluable Myositis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nausea TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.25 [0.01; 5.50]
CheckMate 067 (NI vs I ; all population), 2015 3.53 [0.73; 17.15]
CheckMate 069 (all population), 2015 0.48 [0.03; 7.91]
CheckMate 238, 2017 2.01 [0.07; 59.97]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.45 [0.49 ; 4.30 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 3,360 low not evaluable Nephritis TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Nervous system disorders TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
EORTC 18071, 2015 18.45 [1.07; 319.15]
12.34 [1.59 ; 95.62 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, EORTC 18071, 2015 2 0% 1,671 low not evaluable Neutropenia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.92 [0.06 ; 14.79 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pancreatitis TRAE (grade 3-4)detailed results A3671009, 2013 5.93 [0.30; 118.96]
Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
3.68 [0.39 ; 34.85 ] A3671009, 2013, Ascierto (ipi 10 vs 3 mg/kg), 2017 2 0% 1,370 moderate not evaluable Pancytopenia TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Paraesthesia TRAE (grade 3-4)detailed results KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.46 [0.04 ; 5.09 ] KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 2 0% 1,067 moderate not evaluable Pericarditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
1.99 [0.07 ; 59.56 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Peripheral neuropathy TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 3.99 [0.18; 88.89]
3.99 [0.18 ; 88.89 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pneumonitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 3.00 [0.31; 29.00]
CheckMate 069 (all population), 2015 0.98 [0.09; 11.08]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.92 [0.06; 14.85]
1.57 [0.52 ; 4.72 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 3,181 low not evaluable Polymyalgia Rheumatica TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
0.50 [0.02 ; 14.85 ] Ascierto (ipi 10 vs 3 mg/kg), 2017 1 0% 726 NA not evaluable Pruritic rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.75 [0.16 ; 3.57 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 3,181 low not evaluable Pruritus TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.99 [0.14; 7.10]
CA184-024, 2011 10.35 [0.56; 190.49]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 6.06 [0.73; 50.62]
CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
CheckMate 238, 2017 0.10 [0.01; 1.82]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
1.28 [0.53 ; 3.09 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 11 0% 5,870 low low Pyrexia TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.18; 22.10]
CheckMate 069 (all population), 2015 3.00 [0.15; 61.17]
CheckMate 238, 2017 0.25 [0.01; 5.55]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
1.04 [0.29 ; 3.78 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 6 0% 3,360 low not evaluable Rash TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 2.51 [0.48; 13.01]
CA184-024, 2011 6.16 [0.31; 123.62]
CheckMate 067 (N vs I ; all population), 2015 0.20 [0.02; 1.69]
CheckMate 067 (NI vs I ; all population), 2015 2.02 [0.68; 5.98]
CheckMate 069 (all population), 2015 5.11 [0.27; 95.65]
CheckMate 238, 2017 0.35 [0.13; 0.98]
EORTC 18071, 2015 10.16 [0.55; 186.52]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
MDX010 Ipi plus gp100 vs gp100, 2010 3.51 [0.19; 64.62]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.73 [0.20; 14.97]
MDX010 Ipi vs gp100, 2010 2.02 [0.07; 60.83]
1.38 [0.68 ; 2.82 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 12 26% 6,815 low low Renal and urinary disorders TRAE (grade 3-4) detailed results CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
CheckMate 238, 2017 1.00 [0.02; 50.62]
0.99 [0.08 ; 12.98 ] CheckMate 069 (all population), 2015, CheckMate 238, 2017 2 0% 1,045 low not evaluable Respiratory, thoracic and mediastinal disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 8.03 [0.42; 152.51]
CheckMate 069 (all population), 2015 1.48 [0.15; 14.67]
CheckMate 238, 2017 0.12 [0.01; 2.36]
1.17 [0.13 ; 10.40 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 069 (all population), 2015, CheckMate 238, 2017 3 49% 1,771 low not evaluable Skin and subcutaneous tissue disorders TRAE (grade 3-4) detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.40 [0.44; 4.45]
CheckMate 069 (all population), 2015 9.64 [0.55; 170.02]
CheckMate 238, 2017 0.18 [0.07; 0.46]
EORTC 18071, 2015 42.00 [2.53; 697.02]
MDX010 Ipi plus gp100 vs gp100, 2010 6.38 [0.37; 110.82]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.56 [0.33; 7.34]
MDX010 Ipi vs gp100, 2010 4.08 [0.18; 91.29]
2.34 [0.57 ; 9.58 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CheckMate 069 (all population), 2015, CheckMate 238, 2017, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 7 76% 4,002 low serious Thyroiditis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 1.99 [0.07; 59.56]
CA184-024, 2011 1.02 [0.02; 51.42]
CheckMate 067 (N vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 067 (NI vs I ; all population), 2015 1.99 [0.07; 59.55]
1.49 [0.24 ; 9.13 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, CA184-024, 2011, CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015 4 0% 2,472 low not evaluable Uveitis TRAE (grade 3-4)detailed results Ascierto (ipi 10 vs 3 mg/kg), 2017 0.50 [0.02; 14.85]
KEYNOTE-006 (2 week), 2015 0.92 [0.02; 46.58]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
0.72 [0.08 ; 6.18 ] Ascierto (ipi 10 vs 3 mg/kg), 2017, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 3 0% 1,793 moderate not evaluable Vitiligo TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 1.99 [0.07; 59.55]
CheckMate 067 (NI vs I ; all population), 2015 0.99 [0.02; 50.24]
CheckMate 069 (all population), 2015 0.49 [0.01; 24.92]
MDX010 Ipi plus gp100 vs gp100, 2010 0.35 [0.01; 17.55]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.01; 17.42]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.74 [0.15 ; 3.51 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 6 0% 2,674 low serious Vomiting TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.99 [0.06; 15.96]
CheckMate 067 (NI vs I ; all population), 2015 7.09 [0.87; 57.98]
CheckMate 069 (all population), 2015 0.98 [0.03; 29.71]
KEYNOTE-006 (2 week), 2015 1.84 [0.06; 55.23]
KEYNOTE-006 (3 week), 2015 0.92 [0.02; 46.74]
2.28 [0.62 ; 8.34 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, CheckMate 069 (all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 5 0% 2,455 low serious Weight decreased TRAE (grade 3-4)detailed results CheckMate 067 (N vs I ; all population), 2015 0.50 [0.02; 14.84]
CheckMate 067 (NI vs I ; all population), 2015 0.50 [0.02; 14.84]
KEYNOTE-006 (2 week), 2015 0.46 [0.02; 13.75]
KEYNOTE-006 (3 week), 2015 0.46 [0.02; 13.80]
0.48 [0.09 ; 2.61 ] CheckMate 067 (N vs I ; all population), 2015, CheckMate 067 (NI vs I ; all population), 2015, KEYNOTE-006 (2 week), 2015, KEYNOTE-006 (3 week), 2015 4 0% 2,315 low not evaluable Abdominal pain AE (grade 3-4)detailed results A3671009, 2013 4.04 [1.13; 14.45]
CA184-024, 2011 0.43 [0.11; 1.68]
EORTC 18071, 2015 0.04 [0.01; 0.17]
MDX010 Ipi plus gp100 vs gp100, 2010 0.29 [0.09; 0.87]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.03 [0.21; 5.19]
MDX010 Ipi vs gp100, 2010 0.28 [0.06; 1.36]
0.43 [0.12 ; 1.47 ] A3671009, 2013, CA184-024, 2011, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 6 79% 3,373 low not evaluable Anaemia AE (grade 3-4)detailed results MDX010 Ipi plus gp100 vs gp100, 2010 0.33 [0.14; 0.78]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.95 [0.30; 3.03]
MDX010 Ipi vs gp100, 2010 0.35 [0.11; 1.12]
0.44 [0.23 ; 0.84 ] MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 3 12% 1,286 low not evaluable Asthenia AE (grade 3-4)detailed results A3671009, 2013 0.10 [0.01; 1.78]
CA184-024, 2011 0.17 [0.02; 1.39]
0.14 [0.02 ; 0.77 ] A3671009, 2013, CA184-024, 2011 2 0% 1,142 low not evaluable Chills AE (grade 3-4)detailed results CA184-024, 2011 1.02 [0.02; 51.42]
1.02 [0.02 ; 51.42 ] CA184-024, 2011 1 0% 498 NA not evaluable Colitis AE (grade 3-4)detailed results EORTC 18071, 2015 6.26 [2.61; 15.03]
6.26 [2.61 ; 15.03 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Constipation AE (grade 3-4)detailed results A3671009, 2013 0.98 [0.14; 7.01]
CA184-024, 2011 1.02 [0.02; 51.42]
MDX010 Ipi plus gp100 vs gp100, 2010 1.04 [0.11; 10.11]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.34 [0.07; 1.70]
MDX010 Ipi vs gp100, 2010 3.07 [0.32; 29.91]
0.84 [0.32 ; 2.18 ] A3671009, 2013, CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 5 0% 2,428 low not evaluable Cough AE (grade 3-4)detailed results A3671009, 2013 1.97 [0.07; 58.81]
CA184-024, 2011 2.04 [0.07; 60.99]
EORTC 18071, 2015 0.01 [0.00; 0.15]
MDX010 Ipi plus gp100 vs gp100, 2010 0.69 [0.02; 20.81]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.69 [0.02; 20.65]
MDX010 Ipi vs gp100, 2010 1.01 [0.02; 51.17]
0.43 [0.07 ; 2.75 ] A3671009, 2013, CA184-024, 2011, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 6 45% 3,373 low serious Decreased appetite AE (grade 3-4)detailed results A3671009, 2013 14.32 [1.87; 109.52]
CA184-024, 2011 0.76 [0.17; 3.43]
EORTC 18071, 2015 0.06 [0.01; 0.46]
MDX010 Ipi plus gp100 vs gp100, 2010 0.51 [0.14; 1.85]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 1.03 [0.21; 5.19]
MDX010 Ipi vs gp100, 2010 0.50 [0.09; 2.76]
0.73 [0.23 ; 2.34 ] A3671009, 2013, CA184-024, 2011, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 6 66% 3,373 low not evaluable Diarrhoea AE (grade 3-4)detailed results CA184-024, 2011 21.14 [1.23; 363.94]
EORTC 18071, 2015 0.26 [0.18; 0.37]
MDX010 Ipi plus gp100 vs gp100, 2010 6.13 [0.81; 46.56]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.83 [0.34; 2.05]
MDX010 Ipi vs gp100, 2010 7.40 [0.90; 60.98]
1.99 [0.45 ; 8.85 ] CA184-024, 2011, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 5 87% 2,729 low serious Dyspnoea AE (grade 3-4)detailed results A3671009, 2013 4.00 [0.84; 18.98]
CA184-024, 2011 16.77 [0.96; 293.61]
MDX010 Ipi plus gp100 vs gp100, 2010 0.80 [0.30; 2.14]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.96 [0.34; 2.73]
MDX010 Ipi vs gp100, 2010 0.83 [0.25; 2.80]
1.34 [0.62 ; 2.90 ] A3671009, 2013, CA184-024, 2011, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 5 40% 2,428 low serious Fatigue AE (grade 3-4)detailed results A3671009, 2013 3.90 [1.44; 10.57]
CA184-024, 2011 2.44 [1.21; 4.94]
EORTC 18071, 2015 0.05 [0.03; 0.10]
MDX010 Ipi plus gp100 vs gp100, 2010 1.68 [0.56; 5.04]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.71 [0.31; 1.62]
MDX010 Ipi vs gp100, 2010 2.36 [0.71; 7.87]
1.03 [0.23 ; 4.69 ] A3671009, 2013, CA184-024, 2011, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 6 95% 3,373 low not evaluable Headache AE (grade 3-4)detailed results A3671009, 2013 1.97 [0.18; 21.82]
CA184-024, 2011 4.12 [0.46; 37.08]
EORTC 18071, 2015 0.04 [0.01; 0.11]
MDX010 Ipi plus gp100 vs gp100, 2010 0.46 [0.10; 2.07]
MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010 0.45 [0.10; 2.06]
MDX010 Ipi vs gp100, 2010 1.01 [0.20; 5.09]
0.54 [0.12 ; 2.43 ] A3671009, 2013, CA184-024, 2011, EORTC 18071, 2015, MDX010 Ipi plus gp100 vs gp100, 2010, MDX010 Ipi plus gp100 vs Ipi (EXPLORATORY), 2010, MDX010 Ipi vs gp100, 2010 6 81% 3,373 low serious Hypophysitis AE (grade 3-4)detailed results EORTC 18071, 2015 11.01 [2.57; 47.24]
11.01 [2.57 ; 47.24 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Hypothyroidism AE (grade 3-4)detailed results EORTC 18071, 2015 0.14 [0.02; 1.16]
0.14 [0.02 ; 1.16 ] EORTC 18071, 2015 1 0% 945 NA not evaluable Increase AST AE (grade 3-4)detailed results CA184-024, 2011 18.42 [5.64; 60.14]
EORTC 18071, 2015 0.80 [0.45; 1.45]
3.68 [0.17 ; 79.14 ] CA184-024, 2011, EORTC 18071, 2015 2 95% 1,443 low not evaluable 0.0 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-06-03 15:08 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
pathologies: 2,283,284,70,235,285,68,127,128,286,69,129
- treatments: 504,850,329,558,579,549,868,502,741,556
